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Abstract
Background: In immunoglobulin G4-related kidney disease (IgG4-RKD), focal or diffuse renal cortical atrophy is
often observed in the clinical course after glucocorticoid therapy. This study aimed to clarify the factors related
to renal atrophy after glucocorticoid therapy in IgG4-RKD.
Methods: We retrospectively evaluated clinical features including laboratory data and computed tomography
(CT) findings before and after glucocorticoid therapy in 23 patients diagnosed with IgG4-RKD, all of whom were
followed up for more than 24 months.
Results: Seventeen patients were men, and six were women (average age 62.0 years). Average follow-up period
was 54.9 months. The average estimated glomerular filtration rate (eGFR) at diagnosis was 81.7 mL/min/1.73 m2.
All patients had had multiple low-density lesions on contrast-enhanced CT before glucocorticoid therapy, and showed
disappearance or reduction of these lesions after it. Pre-treatment eGFR and serum IgE level in 11 patients in whom
renal cortical atrophy developed 24 months after the start of glucocorticoid therapy were significantly different from
those in 12 patients in whom no obvious atrophy was found at that time (68.9 ± 30.1 vs 93.5 ± 14.1 mL/min/1.73 m2,
P = 0.036, and 587 ± 254 vs 284 ± 263 IU/mL, P = 0.008, respectively). Pre-treatment eGFR and serum IgE level were
also significant risk factors for renal atrophy development 24 months after the start of therapy with an odds ratio of
0.520 (per 10 mL/min/1.73 m2, 95% confidence interval (CI) 0.273–0.993, P = 0.048) and 1.090 (per 10 IU/mL, 95%
CI: 1.013–1.174, P = 0.022), respectively, in age-adjusted, sex-adjusted, serum IgG4 level-adjusted logistic regression
analysis. Receiver operating characteristic curve analysis showed that eGFR of less than 71.0 mL/min/1.73 m2 and
serum IgE of more than 436.5 IU/mL were the most appropriate cutoffs and yielded sensitivity of 63.6% and specificity
of 100%, and sensitivity of 90.9% and specificity of 75.0%, respectively, in predicting renal atrophy development.
Conclusions: This study suggests that pre-treatment renal insufficiency and serum IgE elevation predict renal atrophy
development after glucocorticoid therapy in IgG4-RKD.
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Background
Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is a
recently recognized systemic fibro-inflammatory disorder
that can affect almost all organs in the body [1, 2]. It fre-
quently causes various renal lesions, which are collectively
referred to as IgG4-related kidney disease (IgG4-RKD) [3].
Many studies have clarified the clinical, radiographic, and
histopathological features of this disease [3–6].
Clinical and histopathological responses to gluco-
corticoid therapy in IgG4-RKD have been characterized
by several recent studies [7–10], and the prognosis of
this disease is not always favorable. Although gluco-
corticoid therapy results in a rapid improvement of
renal function and radiologic findings within one
month after the start of therapy in most cases of IgG4-
RKD, recovery of renal function is suboptimal in the
patients with moderate to severe renal dysfunction be-
fore therapy [8]. Moreover, in the clinical course after
glucocorticoid therapy, focal or diffuse renal cortical at-
rophy is observed in a considerable proportion of
treated patients. However, the factors related to such
renal atrophy have not been well-clarified. This state of
affairs prompted us to undertake the present study to
clarify the factors related to renal atrophy after gluco-
corticoid therapy in IgG4-RKD.
Methods
Patients and materials
Between 1 January 2007 and July 2015, 27 patients with
IgG4-RD were enrolled as candidates for this study from
seven collaborating institutions in Japan. Among them,
we identified 23 patients with IgG4-RKD with typical
renal radiological findings, whose follow-up period was
more than 24 months, and who had sufficient follow-up
data (Table 1). We diagnosed them as having IgG4-RKD
based on their fulfillment of the criteria proposed by the
Japanese Society of Nephrology [3] and exclusion of
other diseases. All patients had IgG4-related involve-
ment of more than one extra-renal organ.
Renal biopsy was performed in 11 patients, and biopsy
of the affected extra-renal organs including salivary and
lacrimal glands in the other 10 patients. All of these 21
patients were diagnosed with definite IgG4-RKD with
typical histopathological and immunohistochemical find-
ings. The remaining two patients fulfilled the diagnostic
criteria of autoimmune pancreatitis (AIP) [11] and
IgG4-related dacryoadenitis and sialoadenitis (IgG4-DS)
[12], respectively, although they were diagnosed with
possible IgG4-RKD. We retrospectively evaluated the
clinical features including laboratory data and imaging
findings at baseline and during the follow-up period in
these 23 patients. The clinical course of all patients was
compatible with that of typical IgG4-RD patients, in-
cluding an initial good response to glucocorticoid. Five
patients (patients 3, 9, 15, 19, and 20 in Additional file
1: Table S1) had been included in our earlier study [13]
and another four patients (patients 13, 17, 22, and 23 in
Additional file 1: Table S1) in another earlier study [7].
Imaging evaluation
All patients underwent whole-body computed tomog-
raphy (CT) examination at the initial diagnosis, and
had evidence of multiple low-density lesions on
contrast-enhanced CT. Follow-up CT data were avail-
able for all 23 patients, who received glucocorticoid
therapy. A single radiologist with extensive experience
in IgG4-RD at Kanazawa University Hospital, who was
blinded to other clinical data including renal function,
reviewed all imaging data.
The sites of renal and extra-renal involvement were
noted at the initial diagnostic CT imaging, and atrophic
change development, improvement of individual pre-
existing renal lesions, and appearance of any new renal
lesions were examined at follow-up CT imaging
Table 1 Baseline clinical characteristics of 23 patients with
IgG4-related kidney disease
Characteristic Value (n = 23 patients)
Age, years 62.0 ± 12.0
Gender, male (%) 73.9
Follow-up period (months) 54.9 ± 22.8
Allergy (%) 65.2
Number of extra-renal organs 3.0 ± 1.3
IgG4 (mg/dL) 1069 ± 533
IgG (mg/dL) 3021 ± 1243
IgE (IU/mL) 429 ± 296
Hypocomplementemia (%) 34.8
CRP (mg/dL) 0.25 ± 0.35
Cr (mg/dL) 1.00 ± 0.48
eGFR (mL/min/1.73 m2) 81.7 ± 25.8
Initial dose of PSL (mg/kg/day) 0.57 ± 0.17




Diabetes mellitus (%) 30.4
Hypertension (%) 21.7
Ischemic heart disease (%) 4.3
Cerebral vascular disease (%) 0
Smoking habit (%) 52.4
Conversion factor for serum creatinine at diagnosis (Cr) mg/dL to μmol/L,
×88.4. ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II
receptor blocker, CRP serum C-reactive protein at diagnosis, eGFR estimated
glomerular filtration rate at diagnosis, IgG serum immunoglobulin G at diagnosis,
IgG4 serum immunoglobulin G4 at diagnosis, IgE serum immunoglobulin E at
diagnosis, PSL prednisolone
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including images within 24 months after the start of
treatment and at the last review. All subsequent CT
scans within 24 months were routinely performed to fol-
low the clinical course and ascertain the efficacy of treat-
ment, while those from 24 months after the start of
treatment to the last review were undertaken for various
reasons including routine monitoring or specific clinical
indications such as suspected relapse.
Atrophic change in renal lesions was defined as a local
dimple in the renal cortex or decrease in the total renal
volume compared with the initial baseline scan, as
judged by the radiologist, who took careful consideration
of the age and constitution of each patient. Radiologic
improvement of renal lesions was defined as recovery of
renal cortical contrast enhancement without atrophic
change as mentioned above at the same site as the low-
density lesion detected at the initial diagnosis.
Definition of clinical improvement and relapse
Clinical improvement in IgG4-RKD was defined as
stabilization or improvement in renal function in terms
of serum creatinine level or estimated glomerular filtra-
tion rate (eGFR) and radiologic improvement as men-
tioned above. Improvement in extra-renal lesions was
identified according to changes in symptomatic, radio-
logic, serologic, and/or histologic features [14, 15].
Relapse of IgG4-RKD was identified by each attendant
physician on the basis of a rapid rise in serum creatin-
ine after careful exclusion of other renal diseases, and/
or reappearance or worsening of the radiologic find-
ings. Relapse of extra-renal lesions was defined as re-
appearance or worsening of symptomatic, radiologic,
serologic, or histologic features [14, 15]. In IgG4-RD,
re-elevation of serological values such as serum IgG or
IgG4 without clinical symptoms or abnormal radiologic
findings was not considered as relapse.
Statistical analysis
Statistical analysis was performed using SPSS V.19. Data
are presented as means ± standard deviation. The signifi-
cance of differences between groups was determined
using the Mann-Whitney U test or Wilcoxon signed
rank test, while the significance of differences in fre-
quencies was analyzed with Fisher’s exact probability
test. For assessment of risk factors for development of
atrophy 24 months after the start of therapy, unadjusted
and age-adjusted, sex-adjusted, serum IgG4 level-
adjusted logistic regression analyses were conducted.
Receiver operating characteristic (ROC) curve analysis
was performed to test the usefulness of certain parame-
ters for the prediction of renal cortical atrophy and to
determine the appropriate cutoff value. Significant dif-
ferences were defined by P < 0.05.
Results
Baseline patient profiles
Baseline clinical characteristics of the 23 patients with
IgG4-RKD and typical renal radiological findings are
listed in Table 1. There were 17 men and 6 women with
an average age of 62 ± 12 years (range 34–77). One
patient (patient 8 in Additional file 1: Table S1) had
been treated with prednisolone at a dose of 7 mg/day
for IgG4-DS. None of the other 22 patients had been
treated with any immunosuppressant drugs, including
glucocorticoids, before the diagnosis of IgG4-RKD. All
patients had involvement of one or more extra-renal
organs (average 3.0 ± 1.3 organs, range 1–7). The salivary
gland was involved in 20 patients (87.0%), the lacrimal
gland in 14 patients (60.9%), the pancreas, a perivascular
lesion, and the lung in 8 patients respectively for each
(34.8%), the retroperitoneum in 3 patients (13.0%), the
prostate and hepatic-biliary tract in 2 patients respectively
for each (8.7%), and a nerve in 1 patient (4.3%). The mean
follow-up period of the 23 patients after diagnosis was
54.9 ± 22.8 months (range 28–93).
At presentation, all patients had elevated serum IgG4
(average 1069 ± 533 mg/dL, range 263–2160, normal
range <105), which was detected using the assay
methods of nephelometry, and IgG (average 3021 ±
1243 mg/dL, range 1756–6729, normal range 870–
1700). There were 16 patients (69.6%) with elevated
serum IgE (average 429 ± 296 IU/mL, range 8–1226,
normal range <250): 8 patients (34.8%) had hypocom-
plementemia. The average serum creatinine level was
1.00 ± 0.48 mg/dL (range 0.40–2.55), and 10 patients
(43.5%) had elevated serum creatinine exceeding
1.0 mg/dL. The average eGFR calculated on the basis of
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equations, which provide the best estimate
for individuals with normal or mildly reduced eGFR
[16], was 81.7 ± 25.8 mL/min/1.73 m2 (range 17.8 –116.6),
and 3 patients (13.0%) had eGFR <60 mL/min/1.73 m2.
Average serum C-reactive protein (CRP) was 0.25 ±
0.35 mg/dL (range 0.0–1.2), and only 2 (8.7%) of 23 pa-
tients had elevated serum CRP (CRP >1 mg/dL) (Table 1)
(see Additional file 1 for more detail on these data).
CT revealed renal parenchymal low-density lesions in
all patients (Fig. 1). These lesions were patchily distrib-
uted hypo-attenuated lesions in the renal parenchyma,
and were single or multiple, and round or wedge-
shaped. Of the 23 patients, 3 also had diffuse thickening
of the renal pelvic wall characterized by a smooth intra-
luminal surface. CT also revealed typical extra-renal
lesions mainly in the salivary glands, lacrimal glands,
pancreas, periaortic/periarterial tissue, and lung.
Diabetes mellitus (DM) was present in seven patients,
hypertension (HT) in five, ischemic heart disease in
only one; none of the patients had cerebral vascular
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disease. Information on smoking history was available
for 21 patients (52.4%), of whom 11 had a past or current
smoking habit.
Treatment
The indications for treatment and the treatment regimen
were decided by the respective attending physician. All
23 patients were treated with prednisolone at an average
initial dose of 35.7 ± 8.3 mg/day (range 20–50) ([0.57 ±
0.17 mg/kg/day (range 0.28–0.97)) after the diagnosis.
The initial prednisolone dose was continued until 2 to
5 weeks after the start of therapy, and gradually tapered
to 2.5–9.0 mg/day in all cases. The average prednisolone
dose at the last review was 6.0 ± 1.7 mg/day. Eighteen
patients were treated with glucocorticoid alone during
the clinical course, and the remaining five patients with
a combination of glucocorticoid and other immunosup-
pressant drugs such as azathioprine, tacrolimus, or
cyclosporine. An angiotensin II receptor blocker (ARB)
was administered to five patients for the treatment of
hypertension during the clinical course; none of the
patients received any angiotensin converting enzyme
inhibitors (ACEI).
Clinical and radiological course after glucocorticoid therapy
After glucocorticoid therapy, all patients had CT evi-
dence of disappearance or reduction of the low-density
lesions during follow up (Fig. 1). Some of the lesions re-
sulted in renal cortical atrophy 24 months after the start
of therapy in 11 patients (group A), whereas no obvious
atrophy was found at that time in 12 patients (group B).
In five patients treated with glucocorticoid and another
immunosuppressant drug during the treatment course, four
patients experienced relapse, and one patient had renal atro-
phy 24 months after the start of therapy. In group A, the
mean duration between initiation of treatment and detection
of atrophy was 8.9 ± 5.4 months. Diffuse thickening of the
renal pelvic wall became thinner or normalized after therapy
in all of three patients. No development of new renal lesions
was observed in any patients under maintenance gluco-
corticoid therapy during follow up. Three-dimensional (3D)
CT was performed in two patients after successful gluco-
corticoid therapy, and revealed the development of multiple
renal cortical scars resembling craters (Fig. 2).
The average eGFR in all 23 patients (81.7 ± 25.8 mL/
min/1.73 m2 before therapy) changed to 85.9 ± 20.7 at
1 month after the start of therapy, 87.6 ± 18.0 at
Fig. 1 Low-density lesions after glucocorticoid therapy. The outcome of low-density lesions after glucocorticoid therapy varied between individual
patients and even between individual lesions: a, c, e, g pre-treatment; b, d, f, h post-treatment. Representative cases are shown: patient 10 (a, b);
patient 15 (c, d); patient 17 (e, f); patient 22 (g, h). Patient 10 had small peripheral cortical nodules. Patients 15 and 17 had multiple, round or
wedge-shaped lesions. Patient 22 had diffuse patchy involvement. Arrows show recovering lesions, and arrowheads show atrophic lesions
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12 months, and 82.0 ± 17.3 at the last review. In group A,
the average eGFR of 68.9 ± 30.1 mL/min/1.73 m2 before
therapy changed to 77.5 ± 22.2 at 1 month after the start
of therapy, 81.8 ± 22.0 at 12 months, and 78.2 ± 21.1 at the
last review. In group B, the average eGFR of 93.5 ±
14.1 mL/min/1.73 m2 before therapy changed to 93.4 ±
16.6 at 1 month after the start of therapy, 93.3 ± 12.2 at
12 months, and 85.5 ± 13.0 at the last review.
Factors related to renal cortical atrophy after
glucocorticoid therapy
To identify the factors related to renal atrophy after gluco-
corticoid therapy, pre-treatment clinical characteristics
including co-morbidities, prednisolone dose, other co-
medication including other immunosuppressant drugs
and ARB, and relapse rate were compared between
groups A and B (Table 2). Pre-treatment eGFR in group
A was significantly lower than that in group B (68.9 ±
30.1 vs 93.5 ± 14.1 mL/min/1.73 m2, P = 0.036). Pre-
treatment serum IgE in group A was significantly higher
than that in group B (587 ± 254 vs 284 ± 263 IU/mL, P =
0.008). None of the other factors significantly differed
between the two groups.
To evaluate the relationship of pre-treatment eGFR
and serum IgE level with development of renal atrophy
24 months after the start of therapy, logistic regression
analyses were performed for various demographic and
clinical variables at baseline. Pre-treatment eGFR and
serum IgE level were significant risk factors for develop-
ment of renal atrophy 24 months after the start of ther-
apy with an odds ratio (OR) of 0.520 (per 10 mL/min/
1.73 m2, 95% CI 0.273–0.993, P = 0.048) and 1.090 (per
10 IU/mL, 95% CI 1.013–1.174, P = 0.022), respectively,
in age-adjusted, sex-adjusted, serum IgG4 level-adjusted
logistic regression analysis (Table 3).
To help determine the ability of eGFR and serum IgE
to reliably predict the development of renal atrophy
after glucocorticoid therapy, and to identify their ap-
propriate cutoffs, we used the ROC curve (Fig. 3). The
area under the ROC curve for eGFR was 0.758 ± 0.111
(95% CI 0.539–0.976, P = 0.036). We found that eGFR
<71.0 mL/min/1.73 m2 was the most appropriate cutoff
that yielded sensitivity of 63.6% and specificity of 100%
in predicting the development of renal atrophy (Fig. 3a).
The area under the ROC curve for serum IgE was
0.826 ± 0.091 (95% CI 0.647–1.000, P = 0.008). Serum
IgE >436.5 IU/mL was the most appropriate cutoff that
yielded sensitivity of 90.9% and specificity of 75.0% in
predicting development of renal atrophy (Fig. 3b).
Discussion
We clarified that radiological abnormalities such as focal
or diffuse renal cortical atrophy developed despite gluco-
corticoid therapy during a 2-year clinical course in about
50% of patients with IgG4-RKD with long-term follow
up. In addition, we investigated the factors that deter-
mine whether or not radiologic abnormalities leave se-
quelae, and found that neither the number of involved
organs nor serum IgG4 levels, but rather renal function
such as eGFR and serum IgE at the time of initiation of
glucocorticoid therapy, were related to the development
of renal cortical atrophy.
In IgG4-RD, good responsiveness to glucocorticoid is
characteristic regardless of which organs are affected
[1, 2, 4–8, 10, 15, 17]. Until now, the response to gluco-
corticoids has been evaluated by means of identifying
radiological abnormalities such as tumefactive or hyper-
plastic lesions, the clinical symptoms caused by them,
and functional parameters of the affected organs,
including renal function [8, 10], salivary secretory function
Fig. 2 Three-dimensional computed tomography (CT). Three-dimensional CT revealed the appearance of multiple renal cortical scars resembling
craters. Patient 22 (c, d) with worse pre-treatment estimated glomerular filtration rate (35.4 mL/min/1.73 m2) than patient 17 (69.3 mL/min/1.73 m2)
(a, b) had many more cortical scars. Arrows show atrophic lesions
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Table 3 Odds ratio for risk of renal atrophy development 24 months after the start of therapy: unadjusted and age-adjusted,
sex-adjusted, serum IgG4 level-adjusted logistic regression
Variable Unadjusted Age-adjusted, sex-adjusted, serum IgG4 level-adjusted
OR 95% CI P value OR 95% CI P value
Age (per year) 1.007 0.939 to 1.080 0.844 1.023 0.948 to 1.104 0.553
Male sex 0.889 0.138 to 5.723 0.901 2.045 0.228 to 18.311 0.522
Allergy 0.400 0.068 to 2.337 0.309 0.327 0.040 to 2.674 0.297
Serum IgG4 concentration at baseline (per 10 mg/dL) 0.988 0.970 to 1.005 0.175 0.983 0.963 to 1.005 0.125
Serum IgG concentration at baseline (per 10 mg/dL) 1.000 0.993 to 1.006 0.938 1.006 0.995 to 1.017 0.270
Serum IgE concentration at baseline (per 10 IU/mL) 1.056 1.004 to 1.111 0.035 1.090 1.013 to 1.174 0.022
Serum C3 concentration at baseline (per mg/dL) 1.001 0.977 to 1.025 0.957 0.995 0.967 to 1.024 0.718
Serum C4 concentration at baseline (per mg/dL) 0.987 0.896 to 1.088 0.795 0.982 0.881 to 1.094 0.740
Serum CH50 titer at baseline (per IU/L) 0.987 0.940 to 1.036 0.585 0.980 0.928 to 1.034 0.452
Serum CRP concentration at baseline (per mg/dL) 2.776 0.208 to 37.079 0.440 6.149 0.273 to 138.380 0.253
eGFR at baseline (per 10 mL/min/1.73 m2) 0.600 0.365 to 0.987 0.043 0.520 0.273 to 0.993 0.048
Number of organs involved 0.715 0.634 to 1.436 0.350 0.793 0.330 to 1.910 0.606
Initial PSL dose (per mg/kg/day) 0.022 0.000 to 6.131 0.184 0.050 0.000 to 54.982 0.402
Other immunosuppressant drugs 0.200 0.019 to 2.162 0.185 0.140 0.010 to 2.041 0.150
ARB 1.875 0.250 to 14.082 0.541 1.008 0.088 to 11.573 0.995
Diabetes mellitus 1.714 0.285 to 10.383 0.556 1.813 0.191 to 17.236 0.605
Hypertension 1.875 0.250 to 14.082 0.541 0.908 0.070 to 11.815 0.941
Smoking habit 0.833 0.150 to 4.636 0.835 0.652 0.091 to 4.655 0.669
Conversion factor for creatinine (Cr): mg/dL to μmol/L, ×88.4. ARB angiotensin II receptor blocker, CI confidence interval, CRP C-reactive protein, eGFR estimated
glomerular filtration rate, OR odds ratio, IgG immunoglobulin G, IgG4 immunoglobulin G4, IgE immunoglobulin E, PSL prednisolone
Table 2 Comparison of patients with and without renal atrophy 24 months after the start of glucocorticoid therapy
Atrophy (+) (n = 11) Atrophy (-) (n = 12) P value
Age (years) 62.6 ± 10.7 61.6 ± 13.5 0.951
Gender (male, %) 72.7 75.0 1.000
Allergy (%) 54.5 75.0 0.400
Number of extra-renal organs 2.8 ± 1.0 3.3 ± 1.6 0.423
IgG4 (mg/dL) 909 ± 587 1216 ± 454 0.065
IgG (mg/dL) 3001 ± 1505 3040 ± 1015 0.424
IgE (IU/mL) 587 ± 254 284 ± 263 0.008
CH50 (IU/L) 31.0 ± 20.5 34.9 ± 14.8 0.498
CRP (mg/dL) 0.31 ± 0.38 0.19 ± 0.32 0.251
Cr (mg/dL) 1.23 ± 0.59 0.80 ± 0.20 0.052
eGFR (mL/min/1.73 m2) 68.9 ± 30.1 93.5 ± 14.1 0.036
Initial dose of PSL (mg/kg/day) 0.52 ± 0.18 0.62 ± 0.16 0.124
Other immunosuppressant drugs (%) 9.1 33.3 0.317
ARB (%) 27.3 16.7 0.640
Relapse (%) 18.2 50.0 0.193
Diabetes mellitus (%) 36.4 25.0 0.667
Hypertension (%) 27.3 16.7 0.640
Ischemic heart disease (%) 0 8.3 1.000
Smoking habit (%) 50.0 54.5 1.000
Conversion factor for serum creatinine at diagnosis (Cr) mg/dL to μmol/L, ×88.4. ARB angiotensin II receptor blocker, CRP serum C-reactive protein at diagnosis,
eGFR estimated glomerular filtration rate at diagnosis, IgG serum immunoglobulin G at diagnosis, IgG4 serum immunoglobulin G4 at diagnosis, IgE serum
immunoglobulin E at diagnosis, PSL prednisolone
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[18], and pancreatic exocrine and endocrine function
[19, 20]. Numerous reports reveal that these indicators
improve at least initially after the initiation of gluco-
corticoid therapy. In type 1 AIP, the clinical picture and
responsiveness to treatment have been investigated
from the earliest period. In this disease, glucocorticoid
therapy was reported to promptly achieve reduction of
local or diffuse pancreatic swelling, improvement of
clinical symptoms, and reduction of serum IgG4 levels
[21]. Also in IgG4-RKD, it was shown that radiological
abnormalities such as multiple low-density lesions,
renal function, and frequently observed hypocomple-
mentemia improved rapidly at the initial stage of gluco-
corticoid therapy [7, 8]. Similarly, an initial good
response to glucocorticoid is generally recognized in
the entire spectrum of IgG4-RD.
However, in contrast to the initial good response to
glucocorticoids, recent studies investigating the long-
term clinical course of IgG4-RD have revealed that dys-
function of the affected organs can persist. Transform-
ation into chronic pancreatitis associated with pancreatic
stones, atrophy, and exocrine and endocrine dysfunction
has been reported in the long-term clinical course of
type 1 AIP [19, 20]. A study investigating the long-term
clinical course in IgG4-RKD showed that patients with
pre-treatment eGFR under 60 mL/min/1.73 m2 calcu-
lated on the basis of the Japanese revised equation for
estimating GFR from serum creatinine [22] attained not
complete but only partial recovery of renal function one
month after the start of glucocorticoid therapy, with re-
sidual dysfunction persisting thereafter, and that radio-
logically, focal or diffuse renal atrophy persisted [8].
Interestingly, renal lesions with complete recovery with-
out any residual atrophy and others with atrophy coex-
isted radiologically under the circumstances in which
global renal function, such as eGFR, improved after
glucocorticoid therapy in this study, highlighting the het-
erogeneity among not only the affected organs but also
individual lesions even within the same organ.
The heterogeneity of individual renal lesions in pa-
tients with IgG4-RKD was also identified histologically.
Raissian et al. analyzed the clinicopathological features
of 35 patients with IgG4-related tubulointerstitial neph-
ritis (TIN), and found that the proportion of fibrosis to
inflammation varied from specimen to specimen, with
some specimens having variability in the extent of fibro-
sis and inflammation within each tissue sample [6]. In a
study comparing light-microscopic findings of IgG4-
RKD with those of other TIN in detail, Yoshita et al. also
reported that all patients with IgG4-RKD had various fi-
brotic stages within each specimen, confirming the results
of the Raissian study [23]. In our earlier study examining
the renal histopathology of post-glucocorticoid treatment
specimens, we found that in some lesions inflammatory
cell infiltrates had disappeared without residual fibrosis,
whereas other lesions developed persistent severe fibrosis
[7]. This histopathological heterogeneity in the progres-
sion of fibrosis may explain why among lesions in
which no radiological differences are detected, some
recover completely without residual atrophy, whereas
others become atrophic.
This study examined the factors related to the devel-
opment of post-treatment renal cortical atrophy associ-
ated with fibrosis, and showed the possibility that pre-
treatment renal function (eGFR) and serum IgE level
could be factors predicting it. Both of these parameters
differed significantly between the patients who devel-
oped renal atrophy after glucocorticoid therapy and
those who did not. Age-adjusted, sex-adjusted, and
serum IgG4 level-adjusted logistic regression analysis
suggested that they were significantly related to develop-
ment of renal atrophy. In addition, the usefulness of
eGFR and serum IgE to predict the development of renal
atrophy was suggested by our ROC curve analysis, in
which the area under the ROC curve was 0.758 and
0.826, showing moderate and high accuracy, respectively.
As the patients with eGFR <71.0 mL/min/1.73 m2 devel-
oped renal atrophy at specificity of 100%, an early initi-
ation of glucocorticoid therapy seems reasonable before
eGFR, which is calculated on the basis of CKD-EPI
equations, declines to about 70 mL/min/1.73 m2. Con-
sidering the heterogeneity of each lesion in the progres-
sion of fibrosis, we can speculate that patients with
lower pre-treatment eGFR had already developed more
lesions with advanced fibrosis and, hence, such lesions
resulted in irreversible atrophic changes despite gluco-
corticoid therapy. In drug-induced interstitial nephritis, a
delay in treatment has been demonstrated to result in
the development of fibrosis and worse renal outcomes
Fig. 3 Receiver operating characteristic curve (ROC) analysis. a ROC
curves to identify the appropriate estimated glomerular filtration rate
(eGFR) cutoffs for the prediction of renal atrophy development show
that eGFR <71.0 mL/min/1.73 m2 yields sensitivity of 63.6% and
specificity of 100% (circle). b ROC curves to identify the appropriate
serum IgE level cutoffs for the prediction of renal atrophy development
show that serum IgE >436.5 IU/mL yields sensitivity of 90.9% and
specificity of 75.0% (circle). AUC area under the curve
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[24]. As the International consensus guidance statement
on the management and treatment of IgG4-RD recom-
mends urgent treatment of IgG4-related tubulointersti-
tial nephritis to prevent irreversible renal failure [25],
further study will be necessary to clarify the benefit of
early initiation of glucocorticoid therapy in IgG4-RKD.
In addition to pre-treatment eGFR, pre-treatment
serum IgE was also identified as a factor significantly
related to development of renal atrophy in this study.
In contrast to pre-treatment renal function, the impact
of serum IgE elevation on renal prognosis has not thus
far been documented in IgG4-RKD. Concerning the
pathophysiology of IgG4-RD, however, upregulation of
T helper (Th) 2 cytokines including interleukin (IL)-4
and IL-13, which promote IgE production, in the affected
lesions have been reported [26–29]. Furthermore, it has
been indicated that such Th2 cytokines, especially IL-13,
play a dominant role in the fibrosis observed in Th2-up-
regulated conditions [30, 31]. On the other hand, Wal-
lace et al. reported that baseline serum IgE elevations, in
addition to elevations in serum IgG4 and blood eosino-
phil counts, could be useful predictors of relapses in pa-
tients with IgG4-RD treated with rituximab [32],
suggesting the significant association between serum IgE
and the clinical course or prognosis in this disease. In
IgG4-RKD, although the precise etiology of elevated
serum IgE remain unclear, it may reflect the upregula-
tion of profibrotic Th2 cytokines that predispose pa-
tients to an increased risk of developing renal atrophy.
This study had several limitations. First, the treatment
regimen and follow-up protocols were inconsistent
among patients because of its retrospective and multi-
institutional nature, complicating the evaluation of the
influence of treatment protocol differences on patient
outcome. Second, although this study included more pa-
tients with long-term, appropriate radiologic follow-up
over 2 years than past ones, the number of patients was
not sufficient to conclude the identified factors to be de-
finitively significant predictors nor the indicated cutoffs
to be optimal in this study. Therefore, larger-scale pro-
spective studies will be needed to confirm our results.
Conclusions
This study suggests that pre-treatment renal insufficiency
and serum IgE elevation can be predictors of renal atrophy
after glucocorticoid therapy, and that starting gluco-
corticoid therapy before eGFR declines to about 70 mL/
min/1.73 m2 may be desirable in IgG4-RKD. Whether
earlier initiation of therapy before renal function de-
clines would more consistently prevent the development
of renal atrophy remains to be confirmed through a
larger-scale prospective study; nevertheless, these obser-
vations should be informative for establishing the opti-
mal treatment strategy for IgG4-RKD.
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